Reuters logo
Celgene profit tops estimates on strong cancer drug sales
July 25, 2013 / 11:46 AM / 4 years ago

Celgene profit tops estimates on strong cancer drug sales

July 25 (Reuters) - Biotechnology firm Celgene Corp reported a quarterly profit above analysts’ estimates as demand for its cancer drugs, Revlimid and Abraxane, remained strong, and the company raised its full-year earnings forecast for the second time.

Second-quarter net income rose to $478.1 million, or $1.11 per share, from $367.4 million, or 82 cents per share, a year earlier.

Excluding one-time items, it earned $1.52 per share. Analysts on average expected a profit of $1.44 per share, according to Thomson Reuters I/B/E/S.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below